Literature DB >> 12783123

Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway.

Yann Roche1, Dominique Pasquier, Jean-Jacques Rambeaud, Daniel Seigneurin, Alain Duperray.   

Abstract

Fibrinogen (fg), present in tumor matrices, has been demonstrated to be determinant in metastatic potential. We have recently shown that fg/ICAM-1 interactions are involved in leukocyte migration across endothelial cell monolayers. Using bladder transitional cell carcinoma as a model, we will show in this study that bladder high grade tumor cell lines express ICAM-1, and that this expression induces an fg-mediated migration. This phenomenon was dependent on ICAM-1/fg interaction as well as RhoA activity. ICAM-1 was concentrated in focal adhesion plaques when tumor cells were allowed to adhere on immobilized fg, suggesting a role in cell migration. The addition of fg induced a 3- to 6-fold enhancement of bladder tumor cell migration through HUVEC monolayers. This process was inhibited by an anti-ICAM-1 antibody blocking fg binding, demonstrating that ICAM-1/fg interaction was involved in the extravasation process. Finally, immunohistological studies revealed that the expression of ICAM-1 was closely associated with an infiltrative histological phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12783123

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  23 in total

1.  The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis.

Authors:  Xingxing Tang; Peng Du; Yong Yang
Journal:  Int J Clin Oncol       Date:  2017-07-27       Impact factor: 3.402

2.  Unraveling the Receptor-Ligand Interactions between Bladder Cancer Cells and the Endothelium Using AFM.

Authors:  Vinoth Sundar Rajan; Valérie M Laurent; Claude Verdier; Alain Duperray
Journal:  Biophys J       Date:  2017-03-28       Impact factor: 4.033

3.  Nephroblastoma overexpressed gene (NOV) enhances RCC cell motility through upregulation of ICAM-1 and COX-2 expression via Akt pathway.

Authors:  Shuai Liu; Liping Han; Xiaoqing Wang; Zheng Liu; Sentai Ding; Jiaju Lu; Dongbin Bi; Yikun Mei; Zhihong Niu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 4.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

Review 5.  Role of tenascins in the ECM of gliomas.

Authors:  Nicole Brösicke; Andreas Faissner
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

6.  Fibrinogen - a possible extracellular target for inositol phosphates.

Authors:  Thomas Grint; Andrew M Riley; Stephen J Mills; Barry V L Potter; Stephen T Safrany
Journal:  Messenger (Los Angel)       Date:  2012-12-01

7.  Morphological analysis of tumor cell/endothelial cell interactions under shear flow.

Authors:  Roxana Chotard-Ghodsnia; Oualid Haddad; Anne Leyrat; Agnès Drochon; Claude Verdier; Alain Duperray
Journal:  J Biomech       Date:  2006-02-23       Impact factor: 2.712

8.  Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma.

Authors:  Hongjie Li; Changying Li; Huili Wu; Ting Zhang; Jin Wang; Shixin Wang; Jiwu Chang
Journal:  Proteome Sci       Date:  2011-04-17       Impact factor: 2.480

9.  The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer.

Authors:  Anirban P Mitra; Arpit A Almal; Ben George; David W Fry; Peter F Lenehan; Vincenzo Pagliarulo; Richard J Cote; Ram H Datar; William P Worzel
Journal:  BMC Cancer       Date:  2006-06-16       Impact factor: 4.430

10.  Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma.

Authors:  Tianxing Dai; Lingrong Peng; Guozhen Lin; Yang Li; Jia Yao; Yinan Deng; Hua Li; Genshu Wang; Wei Liu; Yang Yang; Guihua Chen; Guoying Wang
Journal:  J Gastrointest Oncol       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.